Norovirus Vaccines
Commercial Forecast
Norovirus caused a record run of cruise ship outbreaks across 2025 and into 2026, just as the field's most advanced candidate - HilleVax's HIL-214 - failed decisively in infants and the dominant circulating strain flipped from GII.4 to GII.17 in a single season. ModernaTX's mRNA-1403 remains the clearest path to a licensed norovirus vaccine, though its pivotal Nova 301 trial missed a planned interim efficacy bar in July 2026 and is now enrolling a fourth cohort to confirm the result. This is the independent commercial assessment of that opportunity, published July 2025, drawing on VacZine Analytics' long-standing, independent authority in endemic and institutional vaccine markets.
- Format
- PDF + Excel model
- Coverage
- 113 markets + GAVI
- Vaccines assessed
- mRNA-1403, HIL-214/216, VXA-G1.1
- Markets
- Public & private
- Approach
- Scenario-based
- Base year
- 2025, 2026 refresh optional
- Availability
- Direct licence / bespoke refresh
worldwide every year
economic burden
in the 2024-25 season, up from <10%
case-driven readout
Why norovirus remains an unsolved vaccine problem
Norovirus is simultaneously one of the best-characterised and least controlled pathogens in human gastroenteritis. Understanding its virology, its evasiveness and its institutional footprint is central to understanding where - and to whom - a vaccine can realistically be sold.
Pathogen overview - Norovirus (family Caliciviridae)
Norovirus is a small, non-enveloped, single-stranded RNA virus of the family Caliciviridae, first characterised following a 1968 outbreak of acute gastroenteritis at an elementary school in Norwalk, Ohio, from which its original name - Norwalk virus - was drawn. Human disease is caused predominantly by genogroups GI and GII, subdivided further into genotypes defined by the major capsid protein VP1, of which the GII.4 lineage has been globally dominant for most of the past two decades.
The virus binds histo-blood group antigens (HBGAs) expressed on gut epithelial cells, meaning host genetic secretor status materially affects individual susceptibility. Its infectious dose is extremely low - as few as 10 to 100 viral particles can establish infection - and it is markedly resistant to routine alcohol-based hand sanitisers and many standard surface disinfectants. Transmission occurs via the faecal-oral route, aerosolised vomitus, contaminated fomites and contaminated food and water, most notoriously shellfish and ready-to-eat produce. This combination of low infectious dose, environmental persistence and disinfectant resistance is precisely what makes norovirus so difficult to contain in closed or semi-closed settings.
Those closed settings define the commercial opportunity. Norovirus is the leading cause of acute gastroenteritis outbreaks on cruise ships, in hospitals and long-term care facilities, in schools and military barracks, and it is a leading cause of foodborne illness in high-income countries. Outbreak control in these settings routinely requires ward or venue closure, deep-cleaning protocols and, for cruise operators, direct reputational and regulatory consequences - a cost structure that sits alongside the estimated 685 million cases and roughly 200,000 deaths the virus causes worldwide each year, disproportionately among children under five in lower-income countries.
2024-26 has brought an unusually sharp antigenic shift. Genotype GII.17 accounted for less than 10% of US outbreaks in the 2022-23 season but surged to approximately 75% of outbreaks by 2024-25, overtaking the long-dominant GII.4 lineage and arriving with an earlier seasonal peak than in prior GII.4-dominant years. Parallel surges have been documented in China and Finland across the same period. Substitutions in the GII.17 capsid P2 subdomain, the region that determines antigenicity and receptor binding, may enhance immune evasion - a direct and quantifiable risk factor for any vaccine, including mRNA-1403, that was designed primarily around GII.4-lineage antigens.
ModernaTX leads a pipeline reshaped by one failure and one new strain
No norovirus vaccine has ever been licensed. In the space of eighteen months the presumed frontrunner failed outright in infants, an oral-tablet challenger repositioned around second-generation constructs, and the dominant circulating strain changed. ModernaTX's mRNA-1403 is now the clearest route to approval - and the VacZine Analytics model tracks every scenario around it.
-
ModernaTXReport focus - Phase 3mRNA-1403 Nova 301, launched Sep 2024
Single-dose, lipid-nanoparticle-formulated mRNA vaccine encoding VP1 antigens from three globally prevalent genotypes (GII.4, GI.3 and GII.3), targeting adults aged 18 and over. Phase 1/2 data showed robust HBGA-blocking antibody responses across all three genotypes, supporting initiation of the Phase 3 Nova 301 trial, which aims to enrol up to 25,000 participants and assess prevention of moderate-to-severe acute gastroenteritis. In February 2025 the FDA placed the trial on clinical hold after a single reported case of Guillain-Barre syndrome; the hold was subsequently lifted, Northern Hemisphere enrolment had already completed, and the trial accrued cases through a second Northern Hemisphere season (2025-26). Because the primary endpoint is case-driven rather than time-driven, the Phase 3 readout date itself is a forecasting variable - one this report models explicitly, alongside the commercial implications of the GBS signal and the GII.17 strain shift for a vaccine built around GII.4-lineage antigens. Update, August 2026: Moderna disclosed on 31 July 2026 that Nova 301 missed the statistical bar for early success at a planned interim analysis; the trial remains blinded and ongoing, and a fourth cohort is now being enrolled to strengthen its statistical power. Update, November 2026: On 6 November 2026, reporting Q3 2026 results, Moderna confirmed it does not plan to initiate the previously flagged additional cohort this season and is now engaging with health authorities to determine the mRNA-1403 programme's path forward. -
HilleVaxInfant programme discontinuedHIL-214 (bivalent VLP, adjuvanted) Pivoting to adults
Licensed from Takeda and long regarded as the most clinically advanced norovirus candidate, HIL-214 failed both its primary and secondary efficacy endpoints in the NEST-IN1 Phase 2b infant trial (more than 2,800 infants, US and Latin America), returning a vaccine efficacy of approximately 5%. HilleVax discontinued the infant programme in July 2024 and is now exploring continued development of HIL-214 and next-generation candidate HIL-216 in adult populations, including older adults and higher-risk institutional groups. -
VaxartPhase 1 read out 2025Oral, room-temperature-stable tablet vaccine (VXA-G1.1-NN and successors)
A needle-free, adenovirus-vector oral platform with obvious appeal for mass institutional dosing - cruise crew, military personnel, care-home staff - where cold-chain and injection logistics are a genuine barrier. Second-generation constructs entered a head-to-head Phase 1 trial against first-generation constructs in March 2025 and reported significantly stronger antibody responses in mid-2025. A Phase 2 study could begin as early as the second half of 2025 and a Phase 3 as early as 2026, subject to Vaxart securing a development or commercial partner. -
Second-wave pipelineVariousBroader-coverage VLP and mRNA candidates
Earlier Takeda work (TAK-214, the predecessor deprioritised after HilleVax's spin-out and licence) and a small number of additional VLP and mRNA approaches aimed at wider genotype coverage in direct response to the GII.4-to-GII.17 shift. The report reviews this wider field and its relevance to second-generation, broader-spectrum positioning.
ModernaTX's mRNA-1403 is the defining commercial story in this market, and the reason this is a genuinely unique report. With HilleVax's infant programme discontinued and Vaxart still pre-partnership, mRNA-1403 is the only norovirus candidate in a pivotal trial with a credible near-term path to licensure. But its Nova 301 trial is event-driven rather than calendar-driven, it has already absorbed one regulatory hold over a safety signal, and its trivalent design predates the GII.17 surge that now dominates US, Chinese and Finnish surveillance. VacZine Analytics quantifies the commercial consequences of each of these factors under multiple scenarios, including Moderna's July 2026 interim-analysis update and the resulting fourth-cohort enrolment - something no generic infectious-disease pipeline tracker attempts for this product.
Six analytical layers - one commercial picture
The MarketVIEW norovirus analysis spans disease burden, strain surveillance, the competitive pipeline led by ModernaTX, and scenario-based revenue forecasting across the cruise/hospitality, healthcare, paediatric and travel markets.
Demand modelling for cruise operators, catering and hospitality risk mitigation, and crew or staff vaccination scenarios informed by the record 2025-26 outbreak season.
Hospital and nursing-home outbreak-control programmes, ward-closure cost dynamics and institutional staff-vaccination scenarios.
A ModernaTX-led, head-to-head assessment of mRNA-1403 against HilleVax's HIL-214/216 and Vaxart's oral platform - profiles, trial status, safety signals and commercial implications.
Base, upside and conservative scenarios with explicit assumptions on the case-driven Nova 301 readout, regulatory risk and uptake and pricing across public and private channels.
Updated global epidemiology, the GII.4-to-GII.17 antigenic shift across the US, China and Finland, and the health-economic cost of institutional outbreaks.
Pricing rationale and access dynamics across paediatric and GAVI-eligible public programmes, private travel/consumer channels and institutional procurement contracts.
A glimpse of the commercial model
The table below shows a partial view of the target-population and scenario framework. Full revenue outputs, pricing assumptions and country-level data are in the licensed model.
| Target population | Geography | Market type | Vaccine profile | Revenue scenario |
|---|---|---|---|---|
| Cruise & hospitality workforce | Global operators | Institutional / private | Single-dose, adult | Modelled |
| Hospital & long-term care staff | OECD markets | Institutional | Single-dose | Modelled |
| Paediatric endemic programmes | GAVI-eligible | Public programme | Routine / risk-based | Modelled |
| ██████████ | █████ | ████ | ██████ | $██m (base) |
| ██████████ | █████ | ████ | ██████ | $██m (upside) |
| Total addressable - base | Global | All | All profiles | $███m |
What you receive
A comprehensive intelligence package combining a detailed executive presentation and a fully interactive forecast model - built for decision-makers who need the full picture on the norovirus vaccine opportunity.
- Executive presentation (PDF) - disease background, epidemiology, the GII.17 strain shift, vaccine profiles and full commercial assessment with supporting narrative and references
- Interactive MS-Excel forecast model - volume and revenue outputs with scenario toggles, target-population breakdowns and pricing assumptions across public and private markets
- Scenario-based commercial forecasts - base, upside and conservative cases for cruise/hospitality, healthcare, paediatric and travel segments, with explicit assumptions
- ModernaTX deep-dive - mRNA-1403 trial design, the Nova 301 case-driven timeline and its August 2026 interim-analysis update, the GBS regulatory hold, and the commercial read-across of the GII.17 strain shift
- Competitor intelligence - HilleVax HIL-214/216 post-failure repositioning and Vaxart's oral-platform progress, with partnership and funding risk flagged explicitly
- Updated epidemiology module - global case, death and cost burden, GII.4-to-GII.17 surveillance data from the US, China and Finland, and institutional outbreak-cost benchmarks
Built for organisations weighing the norovirus opportunity
Most valuable to teams evaluating the norovirus market against their own pipeline, BD ambitions or investment thesis - particularly in the context of ModernaTX's Phase 3 programme and the GII.17 strain shift.
Vaccine developers
Positioning, commercial feasibility and target-population prioritisation for norovirus candidates at any stage.
Corporate strategy & BD
Validate market size and structure after HilleVax's infant-trial failure, and understand the competitive landscape around ModernaTX.
Investors & analysts
Independent assessment of market size and pipeline risk for due diligence on norovirus and ModernaTX assets.
Cruise, hospitality & travel-health
Demand modelling for cruise operators, hospitality risk teams and travel-health providers facing a record outbreak season.
Hospital, LTC & public health
Outbreak-control economics and procurement feasibility for healthcare-facility and paediatric public programmes.
Researchers & academia
Comprehensive epidemiology, strain surveillance and the vaccine landscape for grant and translational planning.
This is a genuinely unique report. Most infectious-disease pipeline trackers list norovirus vaccine candidates in passing; almost none combine a rigorous, ModernaTX-specific read of the Nova 301 trial design and its case-driven timeline with an equally rigorous account of the GII.4-to-GII.17 antigenic shift now dominating surveillance in the US, China and Finland. VacZine Analytics has tracked this market since HIL-214 was the presumed frontrunner, and this edition was substantially rebuilt around the two events that changed the field in 2024-26: HilleVax's infant-trial failure and ModernaTX's emergence as the clear Phase 3 leader.
What the report actually gives a client is a way to price uncertainty that generic coverage cannot: scenario ranges for when and whether mRNA-1403 reads out, an explicit valuation of the regulatory risk raised by its GBS signal, and a quantified view of how strain-match risk from GII.17 could affect real-world effectiveness and payer confidence. It combines this with practical commercial segmentation - cruise and hospitality, healthcare and long-term care, paediatric and GAVI-eligible programmes, and travel - that most forecasts treat only in outline. This MarketVIEW edition was published in July 2025 and, unlike a brand-new title, remains available now as a direct licence without any syndication buy-in threshold to clear. A further refresh, incorporating Moderna's Nova 301 interim-analysis disclosure and the outcome of its fourth enrolment cohort, can be commissioned on request; VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market where a faster or more tailored answer is required.
License the July 2025 edition - or commission a refresh
The July 2025 edition of VAMV015 is available now, direct from VacZine Analytics, with single-licence and multi-user options - no syndication buy-in required. Want it brought up to date to reflect Moderna's Nova 301 interim-analysis disclosure and the outcome of the trial's fourth enrolment cohort? A further refresh is available on request, alongside bespoke, ad-hoc norovirus analysis - a briefing call is included on request.